Download or read book MHC Class I Loss and Cancer Immune Escape written by Federico Garrido and published by Springer. This book was released on 2019-05-28 with total page 101 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is about the escape strategies used by cancer cells to avoid the immune response of the host. The main characters of this story are the “Antigen Presenting Molecules” and the “T Lymphocytes”. The former are known as the Major Histocompatibility Complex (MHC): the H-2 and the HLA molecules. The latter are a subgroup of white cells travelling all over our body which are capable to distinguish between “self and non self”. Readers will know from the inside about the history of the HLA genetic system and will discover how T lymphocytes recognize and destroy cancer cells. One of the key important questions is: Why tumors arise, develop and metastasize? This book tries to answer this question and will explain how cancer cells become invisible to killer T lymphocytes. The loss of the HLA molecules is a major player in this tumor escape mechanism. Cancer immunotherapy is aimed at stimulating T lymphocytes to destroy tumor cells. However, the clinical response rate is not as high as expected. The molecular mechanisms responsible for MHC/HLA antigen loss play a crucial role in this resistance to immunotherapy. This immune escape mechanism will be discussed in different types of tumors: lung, prostate, bladder and breast...ect. as well as melanoma and lymphoma. This book will be useful to Oncologists, Pathologists and Immunologist that will enter this fascinating area of research. It will be also interesting for biologist, doctoral students and medical residents interested in “Tumor Immunology”.
Download or read book MHC Class I Antigens In Malignant Cells written by Natalia Aptsiauri and published by Springer Science & Business Media. This book was released on 2013-02-26 with total page 58 pages. Available in PDF, EPUB and Kindle. Book excerpt: Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.
Download or read book Immune Mediated Diseases written by Michael R Shurin and published by Springer Science & Business Media. This book was released on 2007-09-23 with total page 452 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume includes contributions from the speakers of the Second IMD Congress (September 10-15, 2007; Moscow, Russia) who were eager to share some of the academic and clinical enthusiasm that defines the IMD meetings. The goal of the International Immune-Mediated Diseases: From Theory to Therapy (IMD) Congress is to bring the world’s best immunologists and clinicians to Moscow.
Download or read book Antigen Processing and Presentation written by Robert Edward Humphreys and published by . This book was released on 1994 with total page 360 pages. Available in PDF, EPUB and Kindle. Book excerpt: One of the few volumes dedicated to antigen processing, this unique text is not only especially current but also valuable for its description of petentially "hot" areas with its "Future Directions" sections. * Current, important topics covered by this text include: Processing and presentation of foreign and self protein antigens to T lymphocytes Intracellular assembley and transport of MHC proteins Regulation of the assembley and expression of processed antigen-MHC complexes
Download or read book Holland Frei Cancer Medicine written by Robert C. Bast, Jr. and published by John Wiley & Sons. This book was released on 2017-03-10 with total page 2004 pages. Available in PDF, EPUB and Kindle. Book excerpt: Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Download or read book Tumor Immune Escape written by and published by . This book was released on 2005 with total page 276 pages. Available in PDF, EPUB and Kindle. Book excerpt: Changes in HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions. These changes are believed to play a major role in the clinical course of the disease since both HLA class I antigens and NK cell-activating ligands are critical to the interaction between tumor cells and components of both innate and adaptive immune systems. In this study, novel molecular mechanisms underlying HLA class I antigen abnormalities have been identified in melanoma cells derived from malignant melanoma lesions. They include multiple hot-spot CT deletions in the & beta;2 m gene, selective HLA-A2 allospecificity loss, and antigen processing machinery component downregulation, which underlie a HLA class I antigen loss phenotype, as well as single amino acid substitution-carrying, loss-of-functionβ 2m and combined germline/somatic tapasin gene mutations along with selective epigenetic inactivation of HLA-A locus IFN- & gamma; responsiveness, which underlie a HLA class I antigen downregulaiton phenotype. The role of NK cell-activating ligand changes in melanoma immune escape is indicated by the markedly reduced sensitivity to NK cell-mediated lysis in vitro of two of four HLA class I & minus; melanoma cell lines because of their lack of expression of MICA, a ligand for the NKG2D activating receptor. These MHC defects have potential negative impact on both cytotoxic T lymphocyte- and NK cell-mediated anti-tumor responses and thus prompted the development of active specific cancer immunotherapy targeting non-MHC molecules. To this end, the three-dimensional structural basis of tumor antigen mimicry by an anti-idiotypic (id) antibody has been elucidated at the atomic level in the high molecular weight-melanoma associated antigen (HMW-MAA) system. A single complementarity-determining region loop of anti-id antibody MK2-23, which carries the internal image of the nominal HMW-MAA epitope, represents a useful system to investigate which extent of antigen mimicry would maximize the immunogenicity of an antigen mimic. Taken together, the results of my study advance our understanding of the mechanisms underlying the lack of immune control of clinically evident tumors and contribute to the development of alternative cancer immunotherapeutic strategies.
Download or read book Mechanisms of Tumor Escape from the Immune Response written by A Ochoa and published by CRC Press. This book was released on 2002-12-12 with total page 290 pages. Available in PDF, EPUB and Kindle. Book excerpt: The progressive growth of a malignant tumor is accompanied by a decline in the immune response, through mechanisms that have, until recently, been poorly understood. The new era of biological therapies, including cytokines, adoptive transfer of TIL cells, gene therapy and others, brought forth the need to understand the impact of the tumor on the immune system. Moreover, the inability to achieve in humans the unequivocal success of immunotherapy in murine models suggests the possibility that cancer can impair the development of a therapeutic immune response. Scientific and technological advances in cellular and molecular biology during the last two decades have provided new tools with which to explore the dysfunctional immune system of patients with cancer. Novel immunology concepts have provided new insights into changes occurring in tumor cells and the immune system, providing a more cohesive understanding of the process, including: *diminished or absent expression of HLA antigens and co-stimulatory molecules *arrested maturation of dentritic cells *alterations in expression of some signal transduction proteins *increased apoptosis in T and NK cells *presence of suppressor CD+4 and CD25+ T cells Mechanisms of Tumor Escape from the Immune Response provides an introduction to this rapidly developing and, as yet, unsettled area of cancer research, and will be a valuable reference for clinicians and researchers working in the field of cancer immunotherapy.
Download or read book Cancer Immunotherapy at the Crossroads written by James H. Finke and published by Springer Science & Business Media. This book was released on 2003-11-24 with total page 392 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
Download or read book Tumor Immunology and Immunotherapy written by Robert C. Rees and published by Oxford University Press, USA. This book was released on 2014 with total page 469 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor immunology and immunotherapy provides a comprehensive account of cancer immunity and immunotherapy. Examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines, this book provides insight into how these problems may be overcome as viewed by leaders in the field.
Download or read book HLA and Disease Associations written by J.L. Tiwari and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 492 pages. Available in PDF, EPUB and Kindle. Book excerpt: The human leukocyte antigen (HLA) or tissue types are the products of a rapidly developing field of knowledge within the last 20 years. In the early stages of the research many investigators suspected the existence of a complex series of transplantation antigens, but it was widely believed that these antigens would not be well-defined even in this century. Yet in the last two decades as many as 124 different HLA antigens determined by at least 7 very closely linked genes located on the short arm of chromosome 6 have been identified and subsequently agreed upon by an international nomenclature committee. 1 Extensive international collaboration fueled by the potential clinical application of these antigens to clinical transplantation has advanced the field rapidly. There were nine inter national histocompatibility workshops held during this period. Although iden tification of HLA antigens was of primary clinical importance in transplantation 2 and of great basic interest in human genetics and anthropology, a rather un expected bonus has been the determination that HLA antigens are associated with disease susceptibility to a greater extent than any other known genetic marker in man. In the past, many genetic polymorphisms have been suspected to be associated with diseases. The most extensively studied markers are blood groups, enzymes, and serum proteins. A comprehensive account of published studies, totalling approximately 1,000, of these markers is available in a book by Mourant et al.
Download or read book Immune Surveillance written by Richard T. Smith and published by Elsevier. This book was released on 2012-12-02 with total page 553 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immune Surveillance deals with the issues regarding tumor immunology and surveillance, in which the central theme is all about the life span of the mammalian host that is depleted by the environment with mutagenic agents and solutions. The book is divided into six chapters. It includes discussions on the organization and modulation of cell membrane receptors, as well as the origin and expression of membrane antigens. It also covers the topics on the triggering mechanisms for and effector mechanisms activated by the cellular recognition. These topics analyze and evaluate alternatives for the recognition and destruction mechanisms in the knowledge of cell cooperation and requirements for immune recognition. A chapter provides discourse on a solution for the paradox of thriving tumors based on the demonstrable in vitro host immunity. Another discusses the generation of antibody diversity and the theory of self-tolerance. The last chapter explains the evaluation of the evidence for immune surveillance. This reference will be invaluable to those who specialize in immunology.
Download or read book New Prognostic and Predictive Markers in Cancer Progression written by Susan Costantini Alfredo Budillon and published by MDPI. This book was released on 2021-02-12 with total page 294 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Download or read book Cancer Immunology and Immunotherapy written by Mansoor M. Amiji and published by Elsevier. This book was released on 2021-08-27 with total page 548 pages. Available in PDF, EPUB and Kindle. Book excerpt: Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO
Download or read book The Major Histocompatibility Complex MHC HLA in Medicine written by Federico Garrido and published by Springer Nature. This book was released on with total page 116 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Regulation of Cancer Immune Checkpoints written by and published by . This book was released on 2020 with total page 657 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Download or read book Inflammation and Cancer written by Bharat B. Aggarwal and published by Springer. This book was released on 2014-05-12 with total page 489 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume examines in detail the role of chronic inflammatory processes in the development of several types of cancer. Leading experts describe the latest results of molecular and cellular research on infection, cancer-related inflammation and tumorigenesis. Further, the clinical significance of these findings in preventing cancer progression and approaches to treating the diseases are discussed. Individual chapters cover cancer of the lung, colon, breast, brain, head and neck, pancreas, prostate, bladder, kidney, liver, cervix and skin as well as gastric cancer, sarcoma, lymphoma, leukemia and multiple myeloma.
Download or read book Immunotherapy of Melanoma written by Anand Rotte and published by Springer. This book was released on 2016-12-19 with total page 434 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focusses on the different types of immunotherapeutics that are currently being used and developed for the treatment of melanoma. In recent years, immunotherapy has revolutionized the treatment of metastatic melanoma and other types of cancer. Discussing treatment options for melanoma and the success of immunotherapy along with the challenges of immunotherapy, this book covers epidemiology, susceptibility genes, and treatment recommendations from Society for Immunotherapy of Cancer, as well as immune based therapies such as aldesleukin, Intron-A, Sylatron, Yervoy, Opdivo, Keytruda, Imlygic, DC vaccines and adoptive cell therapy. The detailed information included on the key immune cells involved in anti-tumor immune response and immune-inhibitory mechanisms in tumor microenvironment will aid the understanding of tumor immunology. Both academic as well as industry-based researchers, developing novel anti-cancer therapies, will also benefit from the details of promising molecular targets and immunotherapeutic strategies under investigation. With 132 illustrations including synopsis tables for important information, over 1200 references (majority of which are openly accessible) and details of more than 150 ongoing clinical trials, this book is a valuable source of information for health care providers as well as cancer biologists interested in learning about melanoma and the significant advances made by immunotherapy.
